Is there a better way to manage obesity than GLP-1 drugs like Ozempic?
In this episode of Oxford+, host Susannah de Jager speaks with Camilla Easter, CEO of Oxford Medical Products, about Sirona—a pioneering, non-pharmaceutical pill that mimics the effects of bariatric surgery without the side effects. Designed to expand in the stomach and promote satiety, Sirona could become the go-to solution for long-term weight loss and maintenance.
Camilla shares the company’s unconventional startup journey, why they avoided the university spinout route, and how the product is positioned to address global obesity, especially among people who can’t access or tolerate drugs like Ozempic or Wegovy. From the challenges of raising capital in a volatile market to clinical trials and FDA approvals, this episode delivers a rich, inspiring look into medtech innovation with wide-reaching health implications.